BECAUSE WE DON’T BELIEVE THE FUTURE CAN WAIT FOR THE FUTURE

Plenary meeting

January 15, 2019
Safe Harbor

The information in this document has been prepared by Carmat (the “Company”) for information purposes only.

The information contained in this document does not purport to be complete and is qualified by reference in its entirety to the information the Company is required and does make public under the rules and regulations of the Autorité des marchés financiers. The information herein is provided only at the date hereof and may be updated, supplemented, revised, verified or amended. The information herein may be subject to significant changes. The Company is under no obligation to update the information contained herein and any opinion expressed in this document is subject to change without prior notice. Neither the Company nor its subsidiaries, advisors or representatives accept any responsibility or liability whatsoever, for any loss arising from any use of this document or its contents or otherwise arising in connection with this document.

This document contains information regarding the markets in which the Company does business as well as the Company’s competitive position in such markets. This information is extracted from various sources or from estimates provided by the Company. They are not to be relied on in making any investment decision.

This document contains forward-looking statements. These forward-looking statements relate to the Company’s future prospects, developments and strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. By definition, forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements are not a guarantee of the Company’s future performance. The Company’s actual financial position, results and cash flows, as well as the trends in the sector in which the Company operates may differ materially from those contained in this presentation. Furthermore, even if the Company’s financial position, results, cash flows and trends in the sector in which the Company operates conform to those anticipated in the forward-looking statements contained in this presentation, such elements cannot be construed as a reliable indication of the Company’s future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates or to make public any correction to any forward-looking statement in order to reflect an event or circumstance that may occur after the date of this presentation.

Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages are not necessarily equal to the sum of the individually rounded figures, amounts or percentages.

This presentation does not constitute, and is not a part of, an offer or a solicitation to purchase or subscribe for the Company’s securities in any jurisdiction whatsoever. This document, or any part thereof, shall not form the basis of, or be relied on in connection with, any contract, commitment or investment decision.
I. A groundbreaking innovation: the physiological artificial heart

II. Interim results of the PIVOTAL study

III. Strategy and outlook
Speakers

Stéphane Piat  
*Chief Executive Officer of CARMAT*

- Over 20-year experience in the medical device business
- Previously Divisional Vice President Global Market Development at Abbott
- Johnson & Johnson Cordis (2002-2007)

Pr. Christian Latré mouille  
*Cardiac surgeon at the Georges Pompidou European Hospital*

- Principal investigator of the CARMAT bioprosthetic heart feasibility study
Key milestones

- **15 years of R&D** (Airbus Group, Prof. Alain Carpentier)
- **2008**: foundation of CARMAT
- **2010**: IPO on Euronext Growth (previously known as Alternext)
- **2013**: first successful human implantation
- **2014 - 2016**: proof-of-concept in the feasibility study
- **2016**: start of the PIVOTAL study
- **2017**: international expansion of the PIVOTAL study
- **2018**: opening of the **Bois-d’Arcy** facility and approximately **180** employees
A groundbreaking innovation: the physiological artificial heart
Technological breakthrough for the treatment of terminal heart failure

Vision

- A **physiological** artificial heart: a genuine alternative to transplantation
- Make the implantation of this heart a **common surgical procedure**
- Gain a **global market**

CARMAT, the world’s most advanced artificial heart
The total physiological artificial heart: the next opportunity in cardiology

MAJOR PLAYERS

- Medtronic
- Johnson & Johnson
- Boston Scientific
- Abbott
- Edwards

Structural Heart

VAD

AFIB / CRT-D

NYHA evolution

BIVAD*

* BIVAD: Biventricular Assist Device
Clinical development
Advanced Heart Failure

5,000 heart transplants per year

Covering only 3% of the total need

Between 60 and 94% death rate within a year
CARMAT program

Available technology
LVAD/BIVAD/TAH* displaying numerous limitations

Need for a reliable new-generation solution
Adapts to the patient physiology through an autoregulation system and improved hemocompatibility to provide a better quality of life

The objective of the clinical program
Validate these hypotheses

* LVAD: Left Ventricular Assist Device; BIVAD: Bi-ventricular Assist Device; TAH: Total Artificial Heart
# Clinical development

<table>
<thead>
<tr>
<th></th>
<th>FIM Study (completed)</th>
<th>PIVOTAL Study (enrolling)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of patients</strong></td>
<td>4</td>
<td>~ 20</td>
</tr>
<tr>
<td><strong>Selection criteria</strong></td>
<td>INTERMACS 1-2</td>
<td>▪ Inotrope dependent or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ Cardiac index &lt;2.0 L/min/m²</td>
</tr>
<tr>
<td><strong>Primary endpoints</strong></td>
<td>Survival at 30 days</td>
<td>▪ Survival at 180 days or transplanted &lt;180days</td>
</tr>
<tr>
<td><strong>Secondary endpoints</strong></td>
<td></td>
<td>▪ Quality of life, functional recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ 2 years follow up post-implantation</td>
</tr>
</tbody>
</table>
Ongoing PIVOTAL study

- Enrollment completed for the first part of the study
- First patient of the second part of the study enrolled
- Enrollment objective: 20 patients
- Primary endpoint of the study: 6 months survival
Results from the first cohort of the PIVOTAL study

- 6-month survival rate among the first 10 patients: 70%
- Improvement expected with the second patient cohort as a result of the experience gained

<table>
<thead>
<tr>
<th>6-month survival rate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CARMAT FIM</td>
<td>50%</td>
</tr>
<tr>
<td>CARMAT PIVOTAL (part 1)</td>
<td>70%</td>
</tr>
<tr>
<td>SynCardia*</td>
<td>54% - 62%</td>
</tr>
<tr>
<td>BIVAD**</td>
<td>46% - 68%</td>
</tr>
<tr>
<td>LVAD***</td>
<td>90% - 92%</td>
</tr>
</tbody>
</table>

## Confirmation of the FIM study results

- Positive 6-month safety profile in 10 patients compared to other therapies

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Stroke</th>
<th>Bleeding - surgical repair</th>
<th>Gastrointestinal bleeding</th>
<th>Percutaneous cable infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARMAT FIM</td>
<td>0%</td>
<td>75%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td><strong>CARMAT PIVOTAL (part 1)</strong></td>
<td>0%</td>
<td>40%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>SynCardia*</td>
<td>23%</td>
<td>41%</td>
<td>20%</td>
<td>22%</td>
</tr>
<tr>
<td>BIVAD**</td>
<td>7%</td>
<td>n/a</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>LVAD***</td>
<td>8%</td>
<td>14%</td>
<td>8%</td>
<td>10%</td>
</tr>
</tbody>
</table>

** Lavee J et al., J Heart Lung Transplant 2018;37:1399−1402.
*** Netuka I et al., J Am Coll Cardiol 2015;66:2579-89
No hemolysis

- Factors causing hemolysis (red blood cell rupture) negligible for CARMAT
- Hemolysis markers (free plasma hemoglobin) ↓↓ in all patients

<table>
<thead>
<tr>
<th>Factor causing hemolysis is present</th>
<th>LVAD</th>
<th>SynCardia</th>
<th>CARMAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shear stress</td>
<td>++</td>
<td>+++</td>
<td>-</td>
</tr>
<tr>
<td>Synthetic material</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
</tbody>
</table>

Free plasma hemoglobin (mg/L)

- *Intermacs hemolysis cut-off*

PIVOTAL study
No strokes

- CARMAT: hemocompatible by design (materials, operation)
- Modest anticoagulation regime
- Major impact on quality of life and survival

### Anticoagulation recommendation

<table>
<thead>
<tr>
<th>Device</th>
<th>Anticoagulation</th>
<th>Strokes after 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARMAT*</td>
<td>Heparin IV → Heparin SC 75-100 mg aspirin</td>
<td>0%</td>
</tr>
<tr>
<td>SynCardia**</td>
<td>Heparin IV → warfarin INR 2.5-3.5 325mg aspirin, dipyridamole</td>
<td>23%</td>
</tr>
<tr>
<td>BIVAD***</td>
<td>Heparin IV → warfarin INR 2.0-3.0 75-100 mg aspirin</td>
<td>7%</td>
</tr>
<tr>
<td>LVAD****</td>
<td>Heparin IV → warfarin INR 2.0-3.0 75-100 mg aspirin</td>
<td>8%</td>
</tr>
</tbody>
</table>

**** Netuka I et al., J Am Coll Cardiol 2015;66:2579-89

*First cohort of 10 patients
No gastrointestinal bleeding in (first cohort) CARMAT patients thanks to:

- Pulsating flows
- Hemocompatibility
- No shear stress
- No “von Willebrand” failure
- No venous congestion
- Low-dose anti-coagulant

<table>
<thead>
<tr>
<th>Gastrointestinal bleeding after 6 months</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CARMAT*</td>
<td>0%</td>
</tr>
<tr>
<td>SynCardia**</td>
<td>20%</td>
</tr>
<tr>
<td>BIVAD/LVAD***</td>
<td>7%</td>
</tr>
<tr>
<td>LVAD****</td>
<td>8%</td>
</tr>
</tbody>
</table>

*First cohort of 10 patients

** Arabia F et al., J Heart Lung Transplant, 2018;37:1304-1312.
*** Lavee J et al., J Heart Lung Transplant 2018;37:1399–1402
**** Netuka I et al., J Am Coll Cardiol 2015;66:2579-89
LVAD: recurring issue of failure in the unassisted right ventricle

- Failure of the right ventricle in patients treated with LVAD:
  - 6-month incidence: 10%*
  - 24-month incidence: 32%**

- Associated with other undesirable events: congestion, impaired renal function, hepatic impairment, infection

* Netuka I et al., J Am Coll Cardiol 2015;66:2579-89
The prosthesis continues to work as a human heart.

**CARMAT flow rate**
*over 10 months of support*

**Circadian cycle**
*over 10 months of support*
Optimization of the surgical experience

- 100% success rate for the procedure
- Length of surgery shortened with the benefit of experience

- Heart transplantation is possible following the CARMAT implantation: 3/3 successfully completed
- Pre-graft waiting times with CARMAT: between 109 and 243 days
- No tissue adhesion around the CARMAT prosthesis
The device offers major improvements to the patient quality of life:

- Greater mobility
- Regained independence
- Autonomy comparable to LVAD

*Post-transplantation effort*

*Effort with the CARMAT heart*

*Post-transplantation consultation*
Overview of the clinical experience to date

- **Operation**
  - Recovery times comparable to the norm for high-risk patients
  - Physiological autoregulation of the prosthesis, adapted to the activity of the patient

- **Favorable safety profile**
  - No hemolysis, no stroke, no digestive system bleeding in the first cohort

- **Follow-up**
  - 6-month survival rate in the first cohort: 70%
  - Bridge to heart transplant successfully performed

<table>
<thead>
<tr>
<th>Discharge from ICU</th>
<th>11 ± 6 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return home</td>
<td>55 ± 11 days</td>
</tr>
<tr>
<td>Total length of support</td>
<td>5 years (11 patients)</td>
</tr>
</tbody>
</table>
Results better than in the FIM feasibility study

Validation of study objectives

Clinical study in progress, encouraging results waiting for the completion of the second cohort
Strategy and outlook
Upcoming developments

- Ongoing industrial transformation: transfer from Vélizy to Bois-d’Arcy completed

- Completion of the PIVOTAL study

- Obtain FDA authorization to initiate implantation in the United States as part of an Early Feasibility Study (EFS)

- Setting up the sales and marketing strategy: prepare the company for commercialization

All the strategic projects are progressing well
Completion of the PIVOTAL study

- **Enrollment**: 11/20 patients
- **Production**: suspended during the fourth quarter of 2018 to factor in the lessons learned from the analysis of the data collected, representing over 20 years of total operation between clinical trials and reliability test benches
- The **analysis** highlighted **aspects that could be improved** in the manufacturing process, predominantly in the control on integrity and cleanliness of the technical compartment of the prosthesis
- These improvements were implemented in the fourth quarter of 2018, and production resumed in early 2019
- Validation underway for additional centers in two new European countries

The aim is to rapidly complete the enrollment in order to submit the CE marking application in early 2020
Development in the United States

- **Filing for the Early Feasibility Study (EFS) in August 2018**
  - FDA comments currently being addressed
  - consensus achieved regarding the protocol for the study

- **Selection of centers in progress**
  - highly ranked institutions in the field (> 100 cases per year)

- **Recruitment of scientific committee members in progress**

- **Logistical development in preparation**

- **The plan is still to treat the first patients in 2019**
Enhanced financial flexibility

**Financial structure at December 31, 2018**

- Cash and cash equivalents: **€25.2 million**
- **€30 million** loan from the EIB
- Optional equity line: **€24.2 million** in flexible financing under a new agreement with Kepler Cheuvreux

Financial resources able to support the industrial and clinical developments and the preparations for commercialization
CARMAT, a company built to become a leader in its field

➔ Technological breakthrough, unprecedented worldwide: first bioprosthetic heart based on physiological functions

➔ Credible solution to the problems associated with terminal biventricular heart failure, a condition steadily becoming more and more prevalent

➔ Significant clinical and technical progress to submit the CE marking application in early 2020

➔ Support from first-class industrial and financial partners, as well as leading players in cardiology

➔ Acceleration in its transformation towards an industrial and commercial company, to become a leader in its field
Thank you!